{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"4.07"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort -2 (n=2)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"4.28"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort -2 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort -2 (n=2)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"5.11"},{"comment":"Cohort -1 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort -1 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort -1 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort -1 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort -1 (n=2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.02","value":"5.69"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort 1 (n=3)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"8.22"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 1 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort 1 (n=2)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"307.53"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort 2 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"924.66"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 2 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort 2 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"341.21"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort 3 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"265.86"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 3 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort 3 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"288.10"},{"comment":"Cohort 4 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 4 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 4 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 4 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort 4 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"1181.14"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort 5 (n=1)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG000","spread":"NA","value":"1451.43"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort 5 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort 5 (n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"151.19","value":"312.27"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort OCE -1 (n=3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.74","value":"206.43"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort OCE -1 was part of the MEDI3617 Single agent total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort OCE -1 (n=3)"},{"categories":[{"measurements":[{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"386.13"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 1A (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"421.74"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 1A (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"143.16","value":"215.71"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 2A (n=3)"},{"categories":[{"measurements":[{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"228.92"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 2A (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"218.48"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 3A (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"247.51"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 3A (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"257.59","value":"368.08"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 4A (n=4)"},{"categories":[{"measurements":[{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG001","spread":"NA","value":"353.73"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 4A (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"466.27"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 1B (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"750.61"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 1B (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"421.03"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 2B (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"387.45"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 2B (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"141.93"},{"comment":"Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4:Cohort MB 3B (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"109.02","value":"229.19"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MB 4B (n=3)"},{"categories":[{"measurements":[{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG002","spread":"NA","value":"174.65"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MB 4B (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MP1 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MP1 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort MP1 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG003","spread":"NA","value":"339.35"},{"comment":"Cohort MP1 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MP1 (n=1)"},{"categories":[{"measurements":[{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG003","spread":"NA","value":"210.43"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 4: Cohort MP2 (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG003","spread":"NA","value":"166.73"},{"comment":"Cohort MP2 was part of the MEDI3617 + Paclitaxel group.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Cycle 5: Cohort MP2 (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG004","spread":"NA","value":"348.53"}]}],"title":"Cycle 4: Cohort MCP1 (n=2)"},{"categories":[{"measurements":[{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated due to limited sample size (n\\<3).","groupId":"OG004","spread":"NA","value":"336.31"}]}],"title":"Cycle 5: Cohort MCP1 (n=2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"}],"paramType":"MEAN","populationDescription":"All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.","reportingStatus":"POSTED","timeFrame":"Prior to infusion on Cycle 4 and Cycle 5","title":"Circulating Levels of Angiopoietin 2 (Ang2)","type":"SECONDARY","unitOfMeasure":"nanogram per millileter (ng/mL)"}